Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

POOJA P ADVANI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1386876928
CMS profile
335737
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$21,426.76

22 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Stemline Therapeutics Inc. $19,684.77 17
Daiichi Sankyo Inc. $1,370.00 1
Gilead Sciences, Inc. $114.75 1
PUMA BIOTECHNOLOGY, INC. $102.46 1
Exelixis Inc. $99.00 1
AstraZeneca Pharmaceuticals LP $55.78 1

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

POOJA P ADVANI

NPI 1386876928 · CMS profile ID 335737

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386876928?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
POOJA P ADVANI, NPI 1386876928, CMS profile ID 335737. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386876928?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). POOJA P ADVANI, NPI 1386876928, CMS profile ID 335737. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386876928?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
POOJA P ADVANI, NPI 1386876928, CMS profile ID 335737, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1386876928?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

22 matching records · $21,426.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 22 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–22 of 22.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Stemline Therapeutics Inc. $3,120.0009/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142963012 CMS
Stemline Therapeutics Inc. $116.8409/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142963014 CMS
Stemline Therapeutics Inc. $53.0909/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142963016 CMS
Stemline Therapeutics Inc. $3,120.0009/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142963002 CMS
Stemline Therapeutics Inc. $120.8709/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142963004 CMS
Stemline Therapeutics Inc. $2,340.0009/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142963018 CMS
Stemline Therapeutics Inc. $3,120.0009/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142963008 CMS
Stemline Therapeutics Inc. $1,560.0008/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142963006 CMS
Stemline Therapeutics Inc. $73.9507/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142963010 CMS
Stemline Therapeutics Inc. $3.6306/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142962994 CMS
Stemline Therapeutics Inc. $3.5506/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142962996 CMS
Gilead Sciences, Inc. $114.7505/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133797003 CMS
PUMA BIOTECHNOLOGY, INC. $102.4605/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113850092 CMS
Stemline Therapeutics Inc. $3,900.0004/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142962988 CMS
Stemline Therapeutics Inc. $876.0704/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142962990 CMS
Stemline Therapeutics Inc. $12.1104/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142963000 CMS
Stemline Therapeutics Inc. $39.7104/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142962998 CMS
Stemline Therapeutics Inc. $124.9504/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142962992 CMS
Daiichi Sankyo Inc. $1,370.0003/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089391242 CMS
AstraZeneca Pharmaceuticals LP $55.7803/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104498658 CMS
Exelixis Inc. $99.0002/06/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138563876 CMS
Stemline Therapeutics Inc. $1,100.0001/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142962986 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $137.73 2
PY2020 $35.07 2
PY2021 $11.92 1
PY2022 $168.74 4
PY2023 $1,921.82 4
PY2024 $21,426.76 22
PY2025 $18,025.61 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,027,933.01 46
PY2024 Principal investigator $818,849.84 31
PY2023 Principal investigator $325,956.81 50
PY2022 Principal investigator $211,793.99 11
PY2021 Principal investigator $27,412.60 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $42,716.68 12/11/2024 Covered Recipient Teaching Hospital
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130915841
Principal investigator 1 PFIZER INC. $49,667.13 12/02/2024 Non-covered Recipient Entity
MAYO CLINIC
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130904711
Principal investigator 1 PFIZER INC. $21,358.34 11/21/2024 Covered Recipient Teaching Hospital
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130916202
Principal investigator 1 PFIZER INC. $18,934.27 11/12/2024 Non-covered Recipient Entity
MAYO CLINIC
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST No dispute reported 06/30/2026 1130916155
Principal investigator 1 Genentech, Inc. $41,400.00 10/30/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC No dispute reported 06/30/2026 1133401685
Principal investigator 1 PFIZER INC. $21,243.32 10/14/2024 Covered Recipient Teaching Hospital
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130915335
Principal investigator 1 PFIZER INC. $21,358.34 10/14/2024 Covered Recipient Teaching Hospital
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130916206
Principal investigator 1 PFIZER INC. $2,984.96 10/02/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130935173
Principal investigator 1 PFIZER INC. $50,088.39 10/02/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130935518
Principal investigator 1 PFIZER INC. $4,482.80 09/04/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130933174
Principal investigator 1 PFIZER INC. $300.00 09/04/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130933182
Principal investigator 1 PFIZER INC. $12,550.00 09/04/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130935777
Principal investigator 1 PFIZER INC. $42,716.68 08/27/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130933597
Principal investigator 1 PFIZER INC. $10,621.66 08/27/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130934351
Principal investigator 1 PFIZER INC. $39,259.41 08/14/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130935169
Principal investigator 1 PFIZER INC. $42,716.68 08/13/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130935430
Principal investigator 1 PFIZER INC. $31,864.98 07/26/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130933178
Principal investigator 1 PFIZER INC. $53,395.85 07/26/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130934543
Principal investigator 1 PFIZER INC. $10,621.66 07/11/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130933341
Principal investigator 1 PFIZER INC. $3,712.23 06/20/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130935434
Principal investigator 1 PFIZER INC. $1,350.00 06/20/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130935785
Principal investigator 1 PFIZER INC. $21,243.32 06/18/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130935371
Principal investigator 1 PFIZER INC. $64,075.02 06/11/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130934547
Principal investigator 1 PFIZER INC. $54,328.30 06/05/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130935781
Principal investigator 1 PFIZER INC. $64,075.02 04/04/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130935262
Principal investigator 1 PFIZER INC. $33,111.42 04/03/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130934839
Principal investigator 1 PFIZER INC. $300.00 04/03/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130934879
Principal investigator 1 PFIZER INC. $1,350.00 04/03/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130935438
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,376.84 02/16/2024 Non-covered Recipient Entity
MAYO CLINIC NEPHROLOGY AND HYPERTENSION
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) No dispute reported 06/30/2026 1110845183
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,903.23 02/07/2024 Non-covered Recipient Entity
MAYO CLINIC CANCER CENTER
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) No dispute reported 06/30/2026 1110845729
Principal investigator 1 PFIZER INC. $33,743.31 02/01/2024 Non-covered Recipient Entity
MAYO CLINIC FLORIDA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130934424